This trial includes two parts: Part 1 will be a dose finding phase using the modified toxicity probability interval (mTPI) design and Part 2 will be a dose confirmation phase to further examine safety and exploratory efficacy. There are a total of 5 cohorts which will each participate in Part 1 and Part 2. Each cohort can proceed to Part 2 independently after a preliminary RP2D for that cohort is identified in Part 1. In Part 2, approximately 16 additional participants per cohort will be treated at the doses identified using the mTPI design in Part 1 to ensure at least 30 participants are treated at RP2D.